Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Douglas Grossman, MD, Ph.D., co-leader of the Melanoma Center at Huntsman Cancer Institute at the University of Utah (the U) ...

In a study with three UK academic institutions, the platform agreed with MDx results 94 percent of the time in detecting ...

KLF5 appears to fuel pancreatic cancer metastasis by reprogramming epigenetic controls, offering a potential new therapeutic target.

NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

Researchers have developed a highly sensitive light-based sensor that can detect extremely low concentrations of cancer biomarkers in the blood. The new technology could one day make it possible to ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including ...

A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease This retrospective analysis ...

Researchers at Tezpur University in India have identified a panel of circulating microRNAs in blood serum that may help distinguish gallbladder cancer from benign conditions, offering a potential ...

A new Crispr-powered optical blood test detects lung cancer biomarkers at sub-attomolar levels, offering earlier molecular detection than conventional PCR or imaging.